Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agents
Recent advances in drug delivery technology are creating novel therapeutic approaches to the treatment of Parkinson’s disease with levodopa and dopamine agonists. This article reviews those technologies which can be applied to Parkinson’s disease, both for targetting the central nervous system with drugs, as well as for matching the appropriate rate controlled delivery with therapeutic needs. In particular, the possibility exists for eliminating erratic highs and lows of drug delivery to the brain, and to substitute rate controlled, constant drug delivery. Clinical investigations now in progress suggest that new technologies which deliver constant dopaminergic stimulation to patients with Parkinson’s disease may not only eliminate the unpredictable swings in therapeutic efficacy in Parkinson patients with the “on/off” effect, but may even have a role in the future in preventing such fluctuations from developing in patients chronically treated with dopaminergic therapies.
KeywordsDrug Delivery Motion Sickness Growth Hormone Receptor Drug Delivery Device Ommaya Reservoir
Unable to display preview. Download preview PDF.
- Bates IP (1984) The blood brain barrier and central nervous system penetration. Pharm J 30: 265–268Google Scholar
- Costall B, Domeney AM, Naylor RJ (1983) A comparison of the behavioural consequences of chronic stimulation of dopamine receptors in the nucleus accumbens of rat brain effected by a continuous infusion or by single daily injections. Naunyn Schmiedebergs Arch Pharmacol 324: 27–33PubMedCrossRefGoogle Scholar
- Henderson NL (1983) Recent advances in drug delivery systems technology. In: Allen RC (ed) Annual reports in medicinal chemistry. Academic Press, New York, pp 275–284Google Scholar
- Martin-Iverson M, Stahl SM, Iversen SD (1987) Factors determining the behavioural consequences of continuous treatment with 4-propyl-9-hydroxynaphthoxazine, a selective dopamine D2 agonist. In: Rose FC (ed) Parkinson’s disease. J Libbey, London pp 169–177Google Scholar
- Obeso JA, Luquin MR, Martinez-Lage JM (1986 a) Lisuride infusion pump: a device for the treatment of motor fluctuation in Parkinson’s disease. Lancet 1: 467–470Google Scholar
- Obeso JA, Luquin MR, Martinez-Lage JM (1986 b) Intravenous lisuride corrects oscillations of motor performance in Parkinson’s disease. Ann Neurol 19: 31–35Google Scholar
- Stahl SM (1985) New drug delivery systems-a new approach to Parkinson’s disease. In: Marsden CD, Trimble M (eds) Future trends in the treatment of Parkinson’s disease and epilepsy. Franklin Scientific Projects Publications, London, pp 16–18Google Scholar